Nice analogy there Telepanel. The BTD received so far is for apabetalone. As I understand it another BTD for apabetalone has either been applied for already or is in the process of being applied for. That is RVX's news.

As this is a Zenith board we should try to keep this focused on Zenith. I have also heard the same info that you have shared with the board re the success so far in the TNBC trial. If that success continues it wouldn't surprise me to see a BTD applied for for ZEN-3694 at some point during this year on this PI drug as well. If what we are hearing, remission of a metastasized cancer after 3 months, has any legs to it then a BTD would be warranted.

It would seem that additional studies by any companies that have PARP inhibitor programs would also be warranted. In the last or second last presentation I saw it looked like 3694 had been tested with about 30 existing cancer drugs so there should be a few companies with at least a little interest at this time.

As far as not hearing anything from Zenith about this success I also believe there was a blackout on trial data because of an agreement with Pfizer as they are the ones funding this TNBC trial. Taking that thought a little further I also think that blackout agreement finished on March 31st so it shouldn't be to long now before we could be hearing some results. This dovetails very well with Bear's estimate of late April stated in earlier posts.

I must admit, although I have a reasonable position in Zenith I don't pay very much attention to its progress.

Hang in there and stay safe.

tada